HeartBeam (NASDAQ: BEAT) has launched a pilot study to evaluate its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia, a condition characterized by inadequate blood flow and oxygen supply to tissues. The study marks a significant step in developing a device that could address limitations in current patch-based ambulatory monitors, which have historically been unable to detect ischemia or provide clinical-grade insights over extended periods.
Coronary artery disease remains a leading cause of death worldwide, often progressing silently until a major cardiac event occurs. As healthcare providers seek faster and more accessible methods to identify high-risk patients, HeartBeam's technology aims to fill a critical gap. The patch is designed to generate a 12-lead ECG on demand, offering a level of diagnostic detail typically reserved for in-clinic or hospital settings.
According to HeartBeam CEO Robert Eno, “Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time. The HeartBeam patch is designed to change that.” The company believes the device has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
The pilot study will assess the patch's ability to detect signs of ischemia in patients, potentially enabling earlier intervention and improved outcomes. If successful, the HeartBeam patch could offer a non-invasive, convenient solution for continuous cardiac monitoring outside of clinical environments.
For more information about HeartBeam and its technology, visit the company's newsroom at https://ibn.fm/BEAT. Full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially. Factors that could affect outcomes are discussed in the company's filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
